StreetInsider.com News Articles

Form SEC STAFF LETTER BioStem Technologies,

Fri, 16 Oct 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20261016/27198810.html

Form SEC STAFF LETTER BioStem Technologies,

Fri, 16 Oct 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20261016/27198795.html

Form 424B3 BioStem Technologies,

Tue, 13 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261013/27181411.html

Form EFFECT BioStem Technologies,

Tue, 13 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261013/27176288.html

Form 4 BioStem Technologies, For: Oct 07 Filed by: Matuszewski Jason

Fri, 09 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261009/27171856.html

Form 4 BioStem Technologies, For: Oct 07 Filed by: SMITH-VAN VURST ANDREW

Fri, 09 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261009/27171857.html

Form D BioStem Technologies,

Fri, 09 Oct 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20261009/27171633.html

BioStem Technologies CEO and COO buy $1M in stock via options

Thu, 08 Oct 2026 07:02:56 -0400

BioStem Technologies, Inc. (NASDAQ: BSEM) announced that its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstanding stock options, purchasing a combined 500,000 shares of common stock at $2.00 per share, for a total of approximately $1 million.

Each executive exercised options covering 250,000 shares. The purchases were made with cash, according to a press release from the Pompano Beach, Fla.-based company.

"Exercising these options reflects my continued confidence in the Company, our team and the potential for our technology," said Matuszewski. "I believe this capital will support broader sales

BioStem Technologies CEO and COO buy $1M in stock via options

Thu, 08 Oct 2026 07:02:56 -0400

Each executive exercised options covering 250,000 shares. The purchases were made with cash, according to a press release from the Pompano Beach, Fla.-based company.

"Exercising these options reflects my continued confidence in the Company, our team and the potential for our technology," said Matuszewski. "I believe this capital will support broader sales

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

Thu, 08 Oct 2026 07:00:00 -0400

POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstanding options to purchase 250,000 shares of BioStem common stock at an exercise price of $2.00 per share, for a total of 500,000 shares and an aggregate purchase price of approximately $1 million.

“This is an exciting

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

Thu, 08 Oct 2026 07:00:00 -0400

“This is an exciting

Form S-8 BioStem Technologies,

Tue, 06 Oct 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20261006/27156416.html

Form S-1 BioStem Technologies,

Fri, 02 Oct 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20261002/27143672.html

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

Thu, 01 Oct 2026 07:00:00 -0400

POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued one patent and three notices of allowance for additional patent applications and the Mexican Institute of Industrial Property (IMPI) has issued one notice of allowance for additional patent applications.

The newly issued patent and allowed applications broaden BioStem's intellectual property portfolio across its placental and umbilical cord

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

Thu, 01 Oct 2026 07:00:00 -0400

The newly issued patent and allowed applications broaden BioStem's intellectual property portfolio across its placental and umbilical cord

Form 8-K BioStem Technologies, For: Sep 29

Wed, 30 Sep 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260930/27129224.html

BioStem Technologies launches $3M private placement at $4.08 per share

Wed, 30 Sep 2026 08:00:53 -0400

BioStem Technologies Inc. (NASDAQ: BSEM) has entered into definitive agreements for a $3 million private placement, according to a company statement.

The offering consists of 735,296 shares of common stock priced at $4.08 per share, along with two series of warrants — Series A and Series B — each covering up to 735,296 shares. Both warrant series carry an exercise price of $3.83 per share and are exercisable immediately upon issuance.

Series A warrants expire five years after the effective date of the resale registration statement, while Series B warrants expire 24 months after that date. If both warrant series are exercised

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Wed, 30 Sep 2026 08:00:00 -0400

POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company’s common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock, at a purchase price of $4.08 per share and

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Wed, 30 Sep 2026 08:00:00 -0400

Form EFFECT BioStem Technologies,

Wed, 30 Sep 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260930/27124744.html

Form 424B3 BioStem Technologies,

Tue, 29 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260929/27123217.html

Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform

Mon, 21 Sep 2026 16:30:00 -0400

West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.

BioStem Technologies will utilize Terminal1’s integrated suite of shareholder intelligence, investor communications, and digital investor relations tools, giving the company a centralized platform to better understand its shareholder base, communicate with investors, and measure engagement across its investor ecosystem.

The addition of BioStem Technologies represents another step in Terminal1’s continued expansion as public companies increasingly look to consolidate

Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform

Mon, 21 Sep 2026 16:30:00 -0400

The addition of BioStem Technologies represents another step in Terminal1’s continued expansion as public companies increasingly look to consolidate

Form D BioStem Technologies,

Mon, 21 Sep 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260921/27085649.html

Form S-1 BioStem Technologies,

Fri, 18 Sep 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260918/27081341.html